StockNews.com Initiates Coverage on Alimera Sciences (NASDAQ:ALIM)

Equities research analysts at StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a report released on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the stock. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. HC Wainwright downgraded shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price on the stock. in a research report on Tuesday, June 25th. Finally, Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.

Alimera Sciences Stock Down 0.2 %

Shares of Alimera Sciences stock opened at $5.56 on Friday. The firm’s 50 day moving average price is $4.36 and its 200-day moving average price is $3.93. The company has a quick ratio of 2.51, a current ratio of 2.62 and a debt-to-equity ratio of 1.71. Alimera Sciences has a 52-week low of $2.61 and a 52-week high of $5.65. The company has a market cap of $291.29 million, a P/E ratio of -3.54 and a beta of 1.27.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. The firm had revenue of $23.01 million during the quarter, compared to analysts’ expectations of $23.72 million. During the same period in the previous year, the firm earned ($0.71) EPS. On average, sell-side analysts predict that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Institutional Trading of Alimera Sciences

Large investors have recently bought and sold shares of the stock. Fifth Lane Capital LP purchased a new stake in shares of Alimera Sciences in the 1st quarter valued at $83,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Alimera Sciences in the 1st quarter valued at $169,000. Bank of New York Mellon Corp purchased a new stake in shares of Alimera Sciences in the 2nd quarter valued at $344,000. Deltec Asset Management LLC purchased a new stake in shares of Alimera Sciences in the 2nd quarter valued at $690,000. Finally, Ancora Advisors LLC purchased a new stake in shares of Alimera Sciences in the 1st quarter valued at $915,000. Hedge funds and other institutional investors own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).